Identification of cinobufagin and resibufogenin as inhibitors of enterovirus 71 infection

Abstract

In this paper, cinobufagin and resibufogenin were found to inhibit enterovirus 71(EV71) infection in vitro in cell viability and plaque reduction assays. The 50% inhibitory concentrations(IC₅₀) of cinobufagin and resibufogenin were (10.94±2.36) and (218±31) nmol/L, respectively, the 50% cytotoxic concentrations(CC₅₀) of them were (1277±223) and (1385±254) nmol/L, respectively, and the anti-EV71 selectivity index(SI₅₀) of cinobufagin was 116.7, which are promisingly developed into drug. Using a VP1 detection assay and a constructed reporter luciferase, we found that cinobufagin and resibufogenin disrupted the synthesis of EV71 protein. However, neither of them inhibited EV71 RNA replication. Our study suggests that cinobufagin and resibufogenin are the promising candidates that should be further investigated for the treatment of EV71 caused disease.

Keywords

Enterovirus 71 / Coxsackievirus A16 / Cinobufagin / Resibufogenin / Chansu

References

[1] Pourianfar H R, Grollo L. J. Microbiol. Immunol. Infect., 2014.

[2] Yip C C, Lau S K, Woo P C. Emerg. Health Threats J., 2013, 6: 19780.

[3] Yi L, Lu J, Kung H F. Crit. Rev. Microbiol., 2011, 37(4): 313.

[4] Liang Z, Mao Q, Gao F. Front Med., 2013, 7(1): 111.

[5] Li R, Liu L, Mo Z. N. Engl. J. Med., 2014, 370(9): 829.

[6] Zhu F, Xu W, Xia J. N. Engl. J. Med., 2014, 370(9): 818.

[7] Zhu F C, Meng F Y, Li J X. Lancet, 2013, 381(9882): 2024.

[8] Chen T C, Liu S C, Huang P N. J. Biomed. Sci., 2008, 15(3): 291.

[9] Chen T C, Chang H Y, Lin P F. Antimicrob. Agents Chemother., 2009, 53(7): 2740.

[10] Zhang X, Song Z, Qin B. Antiviral Res., 2013, 97(3): 264.

[11] Zhu Q C, Wang Y, Liu Y P. Eur. J. Pharm. Sci., 2011, 44(3): 392.

[12] Yang Y, Xiu J, Zhang X. Molecules, 2012, 17(9): 10370.

[13] Wang J, Chen X, Wang W. J. Ethnopharmacol., 2013, 147(1): 114.

[14] Xu L, Su W H, Jin J. Viruses, 2014, 6: 2778.

[15] Qi J, Tan C K, Hashimi S M. Evid. Based. Complement. Alternat. Med., 2014, 2014: 312684-1

[16] Nakano H, Matsunawa M, Yasui A. Biochem. Pharmacol., 2005, 70(10): 1479.

[17] Akimova O A, Bagrov A Y, Lopina O D. J. Biol. Chem., 2005, 280(1): 832.

[18] Rong X, Ni W, Liu Y. Inflammation, 2014, 37(4): 1050.

[19] Li C, Hashimi S M, Cao S. Evid. Based. Complement. Alternat. Med., 2013, 2013: 849054-1

[20] Chen T, Hu W, He H. Evid. Based. Complement. Alternat. Med., 2013, 2013: 851256-1.

[21] Liang X P, Zhang Z, Hu P. Chem. J. Chinese Universities, 2011, 32(1): 38.

[22] Cui X, Inagaki Y, Xu H. Biol. Pharm. Bull., 2010, 33(10): 1728.

[23] Li X, Fan P, Jin J. Virol. J., 2013, 10: 250-251.

[24] Jin J, Ma H, Xu L. J. Virol. Methods, 2013, 187(2): 362.

[25] Jin J, Xu L, Guo S. Chem. Res. Chinese Universities, 2012, 28(1): 91.

[26] Nijhuis M, van Maarseveen N, Schuurman R. J. Clin. Microbiol., 2002, 40(10): 3666.

[27] Chen T C, Weng K F, Chang S C. J. Antimicrob. Chemother., 2008, 62(6): 1169.

[28] Li Z H, Li C M, Ling P. J. Infect. Dis., 2008, 197(6): 854.

[29] Liu M L, Lee Y P, Wang Y F. J. Gen. Virol., 2005, 86(Pt12): 3263.

[30] Sim A C, Luhur A, Tan T M. Virology, 2005, 341(1): 72.

[31] Wu Z, Yang F, Zhao R. J. Virol. Methods, 2009, 159(2): 233.

[32] Tan E L, Tan T M, Tak Kwong Chow V. Mol. Ther., 2007, 15(11): 1931.

[33] Ooi M H, Wong S C, Mohan A. BMC Infect. Dis., 2009.

[34] Chang L Y, Hsia S H, Wu C T. Pediatr. Infect. Dis. J., 2004, 23(4): 327.

[35] Ooi M H, Wong S C, Podin Y. Clin. Infect. Dis., 2007, 44(5): 646.

[36] Wang S M, Liu C C, Tseng H W. Clin. Infect. Dis., 1999, 29(1): 184.

[37] Lin Y W, Lin H Y, Tsou Y L. PLoS One, 2012, 7(1): e30507.